A share price of Vistagen Therapeutics Inc [VTGN] is currently trading at $2.21, up 10.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VTGN shares have gain 12.18% over the last week, with a monthly amount drifted -7.53%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vistagen Therapeutics Inc [NASDAQ: VTGN] stock has seen the most recent analyst activity on December 07, 2023, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $15 for it. Previously, Maxim Group upgraded its rating to Buy on August 07, 2023, and kept the price target unchanged to $30. On July 22, 2022, downgrade downgraded it’s rating to Mkt Perform. Robert W. Baird downgraded its rating to a Neutral. Jefferies downgraded its rating to a Hold. Robert W. Baird started tracking with a Outperform rating for this stock on May 20, 2021, and assigned it a price target of $9. In a note dated February 18, 2021, Jefferies initiated an Buy rating and provided a target price of $6 on this stock.
Vistagen Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.90 and $4.21. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Vistagen Therapeutics Inc [NASDAQ: VTGN] shares were valued at $2.21 at the most recent close of the market. An investor can expect a potential return of 171.49% based on the average VTGN price forecast.
Analyzing the VTGN fundamentals
Trailing Twelve Months sales for Vistagen Therapeutics Inc [NASDAQ:VTGN] were 0.70M which represents -43.12% decline. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -115.17%, Pretax Profit Margin comes in at -105.78%, and Net Profit Margin reading is -105.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.59 and Total Capital is -0.78. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.05 points at the first support level, and at 1.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.31, and for the 2nd resistance point, it is at 2.42.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vistagen Therapeutics Inc [NASDAQ:VTGN] is 9.35. In addition, the Quick Ratio stands at 9.35 and the Cash Ratio stands at 5.32. Considering the valuation of this stock, the price to sales ratio is 92.06, the price to book ratio is 0.77.
